Fairvalue-Calculator Fairvalue-Calculator
EN DE

Compugen Ltd (CGEN) Fair Value & Analysis

Healthcare · US · Market cap $190M

Price$2.01
Fair Value$5.63
Upside+180.1%
Quality95/100
Evidence: High Range $4.21 – $6.81

Fair value as of: Jun 25, 2026

Analysis

Compugen Ltd (CGEN) currently trades at $2.01, while our model-based Fair Value estimate is $5.63 — implying the stock looks roughly 180.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to addr…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Compugen Ltd (CGEN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $5.63 versus a price of $2.01 — about +180% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CGEN?
Our 21-model fair value for Compugen Ltd is $5.63 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.01.
What is the quality score of CGEN?
Compugen Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.